Shilpa Medicare completes phase-3 trial of novel therapy against nonalcoholic fatty liver disease, shares gain

Shilpa Medicare's shares surged 6.40% on BSE following the successful phase-3 clinical trials of Nor Ursodeoxycholic Acid tablets for Nonalcoholic Fatty Liver Disease. Conducted on 165 patients across India, the trial revealed significant improvements in liver health and reduced fat accumulation with no serious adverse events.